Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Total Current Liabilities (2018 - 2025)

TransMedics (TMDX) has 8 years of Total Current Liabilities data on record, last reported at $89.3 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 49.06% year-over-year to $89.3 million; the TTM value through Dec 2025 reached $89.3 million, up 49.06%, while the annual FY2025 figure was $89.3 million, 49.06% up from the prior year.
  • Total Current Liabilities reached $89.3 million in Q4 2025 per TMDX's latest filing, up from $79.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $89.3 million in Q4 2025 and bottomed at $11.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $41.2 million, with a median of $40.6 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: decreased 21.82% in 2021, then surged 137.33% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $23.2 million in 2021, then rose by 1.82% to $23.7 million in 2022, then surged by 132.17% to $54.9 million in 2023, then grew by 9.06% to $59.9 million in 2024, then soared by 49.06% to $89.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $89.3 million in Q4 2025, $79.7 million in Q3 2025, and $56.6 million in Q2 2025.